XELTIS
2.12.2014 13:01:41 CET | Business Wire | Pressemeddelelse
Xeltis , a privately-held medical device company dedicated to transforming standards of care in heart valve replacement and vascular surgery, has announced that it has raised EURO 27 million (USD 34 million/CHF 32 million) in an oversubscribed Series B financing. Life Sciences Partners, Amsterdam (LSP) and Kurma Partners, Paris (Kurma) led the round, with participation from VI Partners, Zug (VI) and current shareholders of Xeltis. The financing will primarily be used to fund market access activities for the company’s first product, a pulmonary valve, and the development of the company’s product pipeline. The replacement pulmonary valve will be used to treat the orphan pediatric indication of severe congenital malformations of the heart.
Xeltis is developing synthetic biodegradable heart valves and blood vessels (“matrices”), enabling a completely new therapeutic category called Endogenous Tissue Growth (“ETG”). Xeltis’ proprietary technology, based on Nobel prize-winning science, is designed to stimulate and guide the body’s natural healing response from the inside, leading to spontaneous growth of new valves and vessels within the body, once the matrices are implanted. The matrices are intended to biodegrade as natural tissue grows, leaving no foreign material behind. Xeltis holds the promise to enable ETG for the first time.
“We believe that Xeltis has the potential to bring a complete paradigm shift in cardiac and vascular surgery,” said Clemens van Blitterswijk, partner at LSP. “The uniqueness and the breakthrough nature of their technology make Xeltis a very attractive investment opportunity“. Vanessa Malier, partner at Kurma, added: “We were impressed by the broad potential of Xeltis’ breakthrough technology and by the team’s achievements in turning it into game-changing products in cardiology and surgery. Xeltis’ first product will target rare cardiac malformations affecting children. This investment fits perfectly with our fund strategy and we are excited to support the development of the company.”
“This investment marks a significant milestone for Xeltis. Having preeminent investment firms join forces with us gives us the means to fulfill our ambitious objective, which is to improve the lives of millions of patients”, said Laurent Grandidier, Chief Executive Officer. “Our ongoing clinical studies and our extensive pre-clinical testing have created a solid foundation of evidence supporting the feasibility, safety and versatility of our technology. This financing speaks to the tremendous clinical value Xeltis is anticipated to provide to patients and physicians.”
About Endogenous Tissue Growth
Endogenous Tissue Growth (ETG) is a therapeutic category in which surgeons use synthetic biodegradable implants designed to allow the body to repair itself by spontaneously growing natural, healthy tissue from the inside. Because the tissue produced through ETG is the patient’s own, the treatment has the potential to overcome the limitations of current standard of care. No foreign material is permanently implanted in the body, so long-term medication may no longer be needed. In addition, the risk of repeated surgeries may be reduced.
For more information, visit http://www.xeltis.com
About Life Sciences Partners - For information, visit http://www.lspvc.com
About Kurma Partners - For information, visit http://www.kls-partners.com/
About VI Partners – For information, visit http://www.vipartners.ch
CAUTION: INVESTIGATIONAL DEVICE.
No. No. No.
German and French versions of this release available at http://www.xeltis.com/media-kit/
Contact:
Genevensis Healthcare Communications
Danièle A. Castle
Email: daniele.castle@genevensis.com
Tel:
+ 41 79 202 6667
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Almarai Launches the 2026 Cycle of the World’s Largest Award for Food Security Research in Dryland Regions3.6.2026 16:31:00 CEST | Press release
The Almarai Prize - the international track of the Almarai Prize for Scientific Creativity - invites leading global research institutions and PhD‑holding scientists to nominate standout research that advances food security in dryland regions. Self‑nominations are not allowed; only PhD‑level nominators may submit, and institutions may nominate up to three projects. The prize totals USD 500,000 (SAR 1,875,000), awarded to one winning research project or institution. The 2026 cycle of the Almarai Prize, international track of the Almarai Prize for Scientific Creativity, has officially opened, calling on leading research institutions, distinguished scientists, and global experts to nominate pioneering research that advances food security in the world’s driest regions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603753914/en/ Almarai Launches the 2026 Cycle of the World’s Largest Award for Food Security Research in Dryland
Stabilizing Grids and Cutting Costs in Half: Europe Is Banking on Grid-Relevant Storage Systems3.6.2026 15:50:00 CEST | Press release
The European battery market is scaling up at record speed: According to the latest Solar+ Report from SolarPower Europe, at the end of 2025, the installed storage fleet in the EU had reached a total capacity of 40 gigawatts (GW) and a storage capacity of 77 gigawatt hours (GWh). This is an increase of over 45 percent compared to the previous year. By 2030, the study’s Solar+ scenario forecasts that capacity will quadruple to 171 GW, while storage capacity will increase eightfold to 598 GWh. As growing solar and wind capacities place increasing demands on European grids, storage systems will need to shift electricity over many hours. As a result, the average storage duration will go up from 1.9 to 3.5 hours. This represents a technological leap that underscores the need to establish more grid-relevant storage systems. Taking place in Munich from June 23–25, ees Europe will showcase how the industry is meeting this enormous demand. As Europe’s largest exhibition for batteries and energy
2026 World Cup Triggers Corporate Travel Boom in Canada and U.S.3.6.2026 15:00:00 CEST | Press release
Navan data reveals Canadian business bookings have tripled, while U.S. hotel prices spike 30% as global enterprises lock in client entertainment Navan (NASDAQ: NAVN), the global AI-powered business travel and expense management platform, today released year-over-year data revealing global enterprises are leaning in heavily to the upcoming 2026 World Cup, with hotel and flight bookings for business travel to World Cup host cities up 46% to the U.S. and a massive 295% to Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602020779/en/ Navan data reveals Canadian business bookings have tripled, while U.S. hotel prices spike 30% as global enterprises lock in client entertainment “While headlines right now are focusing on softer-than-expected tourism demand and lagging leisure hotel bookings, our corporate data tells a different story,” said Dane Molter, SVP, Navan Group Travel Marketplace. “Companies are embracing the Wor
Onimusha: Way of the Sword Set to Release on September 25, 2026!3.6.2026 15:00:00 CEST | Press release
– A playable demo will be released ahead of the game’s launch – Capcom Co., Ltd. (TOKYO:9697) today announced that Onimusha: Way of the Sword, the latest title in the Onimusha series, is scheduled for release on September 25, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603903549/en/ Onimusha: Way of the Sword key art Onimusha: Way of the Sword, which marks the first new title in the series in over 20 years, is a Japanese-inspired dark fantasy game that features Miyamoto Musashi as the protagonist and is set in an Edo-era Kyoto that has been twisted by malevolent clouds of Malice. Capcom is developing the title with the aim of appealing to a wide range of players through its exhilarating sword-based action and highly-unique characters. Ahead of launch, the company released a playable demo today*, June 3, 2026, titled Onimusha: Way of the Sword DEMO, to give players an opportunity to enjoy the appeal of the game as
Private Markets Firms Face SPV Execution Pressure as LP Demands Rise3.6.2026 14:30:00 CEST | Press release
86% of private markets professionals report rising LP requests for tailored SPV arrangementsTransparency and reporting rank as the top LP priority, cited by 76% of respondents82% report increased demand for single-asset SPVs amid growing liquidity and execution pressures As private markets firms navigate a more challenging fundraising and exit environment, limited partners (LPs) are demanding greater transparency, stronger governance rights, and more flexible SPV arrangements from fund managers. In fact, 86% of private markets professionals report increased LP requests for tailored SPV structures over the past 12 months, according to a new study by CSC, the leading provider of global business administration and compliance solutions. CSC¹ surveyed 410 senior private markets practitioners across private equity, private credit, real estate, and infrastructure to examine how investor demands are reshaping SPV structures, operating models, and execution requirements. The findings are detail
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum